Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000073" target="_blank" >RIV/00209805:_____/16:N0000073 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/17:00095942 RIV/00216208:11110/17:10360695 RIV/00216208:11130/17:10360695 RIV/61989592:15110/17:73583812 and 4 more

Result on the web

<a href="http://link.springer.com/article/10.1007%2Fs11523-016-0458-1" target="_blank" >http://link.springer.com/article/10.1007%2Fs11523-016-0458-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11523-016-0458-1" target="_blank" >10.1007/s11523-016-0458-1</a>

Result language

angličtina

Original language name

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

Original language description

To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients' characteristics, disease history, cancer treatments, response to treatments and safety. A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/LM2015090" target="_blank" >LM2015090: Czech National Node to the European Clinical Research Infrastructure Network</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Targeted oncology

ISSN

1776-2596

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

1

Country of publishing house

CH - SWITZERLAND

Number of pages

7

Pages from-to

89–95

UT code for WoS article

000393121700009

EID of the result in the Scopus database

—